| __timestamp | ADMA Biologics, Inc. | Celldex Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 3742367 | 101881000 |
| Thursday, January 1, 2015 | 4311461 | 4011000 |
| Friday, January 1, 2016 | 6360761 | 102026000 |
| Sunday, January 1, 2017 | 29164321 | 96171000 |
| Monday, January 1, 2018 | 42194635 | 66449000 |
| Tuesday, January 1, 2019 | 39504238 | 42672000 |
| Wednesday, January 1, 2020 | 61291426 | 42534000 |
| Friday, January 1, 2021 | 79769341 | 3068000 |
| Saturday, January 1, 2022 | 118814535 | 1400000 |
| Sunday, January 1, 2023 | 169273000 | 3008000 |
Unveiling the hidden dimensions of data
In the dynamic world of biotechnology, understanding financial trends is crucial for investors and stakeholders. This analysis delves into the cost of revenue for two pioneering companies: ADMA Biologics, Inc. and Celldex Therapeutics, Inc., from 2014 to 2023.
ADMA Biologics has shown a remarkable upward trajectory, with its cost of revenue increasing by over 4,400% from 2014 to 2023. This growth reflects the company's expanding operations and market presence. In contrast, Celldex Therapeutics experienced a significant decline, with a 97% reduction in cost of revenue over the same period, indicating strategic shifts or operational downsizing.
These contrasting trends highlight the diverse strategies within the biotech sector, offering insights into how companies adapt to market demands and technological advancements.
Cost of Revenue Trends: Eli Lilly and Company vs Celldex Therapeutics, Inc.
Amgen Inc. vs Celldex Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Bio-Techne Corporation vs Celldex Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
ADMA Biologics, Inc. vs CRISPR Therapeutics AG: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: ADMA Biologics, Inc. vs Xenon Pharmaceuticals Inc.
Cost Insights: Breaking Down ADMA Biologics, Inc. and ACADIA Pharmaceuticals Inc.'s Expenses
Analyzing Cost of Revenue: ADMA Biologics, Inc. and Perrigo Company plc
Cost of Revenue: Key Insights for ADMA Biologics, Inc. and Veracyte, Inc.
Cost of Revenue Trends: ADMA Biologics, Inc. vs HUTCHMED (China) Limited
Cost of Revenue Trends: ADMA Biologics, Inc. vs Supernus Pharmaceuticals, Inc.
Cost of Revenue: Key Insights for Iovance Biotherapeutics, Inc. and Celldex Therapeutics, Inc.
Analyzing Cost of Revenue: Celldex Therapeutics, Inc. and Viridian Therapeutics, Inc.